Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biotime Inc (BTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 295,607
  • Shares Outstanding, K 126,870
  • Annual Sales, $ 3,460 K
  • Annual Income, $ -19,980 K
  • 36-Month Beta 1.86
  • Price/Sales 85.12
  • Price/Cash Flow N/A
  • Price/Book 2.87

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.98 +17.68%
on 07/02/18
2.42 -3.72%
on 06/19/18
+0.09 (+4.02%)
since 06/13/18
3-Month
1.98 +17.68%
on 07/02/18
2.54 -8.27%
on 04/16/18
-0.16 (-6.43%)
since 04/13/18
52-Week
1.98 +17.68%
on 07/02/18
3.16 -26.27%
on 01/29/18
-0.82 (-26.03%)
since 07/13/17

Most Recent Stories

More News
BioTime (BTX) in Focus: Stock Moves 7.3% Higher

BioTime (BTX) was a big mover last session, as the company saw its shares rise more than 7% on the day.

ILMN : 306.99 (+0.75%)
BTX : 2.33 (+0.43%)
Detailed Research: Economic Perspectives on Verizon Communications, PayPal, Menlo Therapeutics, iClick Interactive Asia Group, BioTime, and Adobe -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Verizon Communications Inc....

PYPL : 87.99 (-1.28%)
MNLO : 8.40 (+1.45%)
VZ : 51.41 (+0.33%)
BTX : 2.33 (+0.43%)
ADBE : 258.59 (+1.46%)
ICLK : 6.54 (+4.14%)
BioTime (BTX): Moving Average Crossover Alert

BioTime, Inc. (BTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

BTX : 2.33 (+0.43%)
SmarTrend Watching for Potential Rebound in Shares of Biotime Inc After 1.87% Loss

Biotime Inc (AMEX:BTX) traded in a range yesterday that spanned from a low of $2.30 to a high of $2.44. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $2.40 on volume...

BTX : 2.33 (+0.43%)
BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session

BioTime (BTX) was a big mover last session, as the company saw its shares rise 6% on the day amid huge volumes.

PTGX : 7.45 (+0.27%)
BTX : 2.33 (+0.43%)
BioTime - A Multi-Faceted Regenerative Medicine Company

BEND, OR / ACCESSWIRE / September 22, 2017 / BioTime, Inc. (NASDAQ: BTX), Sylva International has always been extremely interested in regenerative medicines because they've shown tremendous promise in...

CDXC : 4.56 (-2.15%)
BTX : 2.33 (+0.43%)
AgeX Therapeutics CEO Michael D. West to Participate in Fireside Chat with J. Craig Venter at the Cell & Gene Therapy CEO Forum

AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announces that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime,...

BTX : 2.33 (+0.43%)
BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Co-Chief...

BTX : 2.33 (+0.43%)
BioTime to Present at the Ladenburg Thalmann 2017 Healthcare Conference

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty,...

BTX : 2.33 (+0.43%)
BioTime Awarded Grant from the NIH

--Accelerates Retinal Restoration Program

BTX : 2.33 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade BTX with:

Business Summary

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body....

See More

Key Turning Points

2nd Resistance Point 2.38
1st Resistance Point 2.35
Last Price 2.33
1st Support Level 2.29
2nd Support Level 2.25

See More

52-Week High 3.16
Fibonacci 61.8% 2.71
Fibonacci 50% 2.57
Fibonacci 38.2% 2.43
Last Price 2.33
52-Week Low 1.98

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar